MENLO PARK, Calif.--(BUSINESS WIRE)--Nevro Corporation has announced the appointment of Michael DeMane as President and Chief Executive Officer effective immediately. He will also join the company's Board of Directors.
Mr. DeMane is a veteran medical device company executive, having held leadership roles in the US, Europe and Australia over the past 30 years. His most recent operating role was COO of Medtronic, Inc. (MDT) and prior to that he served as Medtronic’s Senior Vice President and President Europe, Canada, Latin America and Emerging Markets directing the company's operations in those regions.
Nevro Corporation has developed a novel therapy for spinal cord stimulation (SCS) for the treatment of chronic back and leg pain based on intellectual property licensed from the Mayo Clinic. The neuromodulation technology is designed to provide pain relief without side effects such as paresthesia and movement induced jolting. The Nevro SCS system is approved for commercial use in Europe.
Mr. DeMane succeeds company founder and CEO Konstantinos Alataris, PhD, who will remain with the company and continue as a Director of the company.
“I am extremely excited to work with Dr. Alataris and the Nevro organization as well as leading clinicians around the world to make this therapy available to patients,” said DeMane. “I believe that the Nevro platform has the potential to significantly advance the treatment of chronic back and leg pain.”
Nevro has been established with one vision: To provide relief of chronic back pain. Nevro’s proprietary spinal cord stimulation (SCS) system is designed to advance the promise of SCS by delivering significant and sustained pain relief free from side effects. Nevro therapy is also designed to simplify the implant procedure.
The Nevro System has received the CE mark and is now commercially available at select centers in Europe. Nevro is headquartered in Menlo Park, California. For more information, visit www.nevro.com.